Targeted-release budesonide in immunoglobulin A nephropathy; a mini-review

Targeted-release budesonide in immunoglobulin A nephropathy; a mini-review

Immunoglobulin A nephropathy is the most common kind of primary glomerulonephritis worldwide and one of the main causes of renal failure. Systemic corticosteroid therapy may protect against renal deterioration in IgA nephropathy; however, it is not often advised for long-term treatment due to possib...

Full description

Bibliographic Details
Main Authors:	Shiva Toumaj, Shahrzad Alimohammadi, Maryam Ghasemi, Shokouh Shayanpour
Format:	Article
Language:	English
Published:	Society of Diabetic Nephropathy Prevention 2023-06-01
Series:	Journal of Nephropharmacology
Subjects:	iga nephropathy budesonide corticosteroids immunosuppressive therapy glomerulonephritis end-stage kidney disease
Online Access:	https://jnephropharmacology.com/PDF/npj-12-e10605.pdf

Similar Items

Study on the Mechanism of Budesonide in the Treatment of IgA Nephropathy Based on Network Pharmacology
by: ZHANG Kang, ZHAO Tingting, ZHANG Bo, GAO Mengqi, LI Yuxi, WANG Shaopeng, ZHAO Wenjing
Published: (2023-12-01)

Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review
by: Jian Liao, et al.
Published: (2023-01-01)

Diagnosing and Treating IgAN: Steroids, Budesonide, or Maybe Both?
by: Christodoulos Keskinis, et al.
Published: (2024-02-01)

Recurrent Immunoglobulin A Nephropathy after Kidney Transplant—An Updated Review
by: Hwarang S. Han, et al.
Published: (2023-09-01)

A multicenter, randomized, open-label, comparative, phase IV study to evaluate the efficacy and safety of combined treatment with mycophenolate mofetil and corticosteroids in advanced immunoglobulin A nephropathy
by: Sang Youb Han, et al.
Published: (2022-07-01)

Role of corticosteroid therapy in IgA nephropathy; where do we stand?
by: Shankar Prasad Nagaraju, et al.
Published: (2017-10-01)

The Effect of Hydroxychloroquine on Residual Proteinuria in Patients With Immunoglobulin A Nephropathy: A Retrospective Study Based on Propensity Score Matching
by: Mijia Liu, et al.
Published: (2022-07-01)

Primary IgA nephropathy: current challenges and future prospects
by: Penfold RS, et al.
Published: (2018-04-01)

Infection-related immunoglobulin A nephropathy or IgA-dominant postinfectious glomerulonephritis; what is in a name?
by: Ghazal Ghasempoor Dabaghi, et al.
Published: (2021-07-01)

Advances in IgA nephropathy management, from pathological insights to personalized treatment
by: Mitra Shavakhi, et al.
Published: (2023-09-01)

Combining clinical features and MEST-C score in IgA nephropathy may be a better determinant of kidney survival
by: Yeter Hasan Haci, et al.
Published: (2020-12-01)

Promising role of sodium-glucose cotransporter-2 inhibitors in IgA nephropathy
by: Samaneh Zandifar, et al.
Published: (2023-06-01)

Clinical Significance of Crescent Formation in IgA Nephropathy – a Multicenter Validation Study
by: Sehoon Park, et al.
Published: (2019-02-01)

Immunoglobulin A Nephropathy. Recurrence After Renal Transplantation
by: Gabriella Moroni, et al.
Published: (2019-06-01)

Do IgA nephropathy presentations display any seasonality?
by: Adrian Y. S. Lee, et al.
Published: (2021-07-01)

Use of corticosteroids in Norwegian patients with immunoglobulin a nephropathy progressing to end-stage kidney disease: a retrospective cohort study
by: Mariell Rivedal, et al.
Published: (2024-01-01)

The Effect of Budesonide that is the Topical Corticosteroid on the Rat Nasal Mucosa (Experimental Study)
by: Atila Güngör, et al.
Published: (2002-03-01)

Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with Immunoglobulin A Nephropathy (IgAN) in the United States
by: Ramjee L, et al.
Published: (2023-03-01)

Relapses or de-novo IgA nephropathy following COVID-19 vaccination; a narrative review
by: Masoud Hafizi, et al.
Published: (2023-03-01)

Kartagener syndrome complicated by immunoglobulin A nephropathy
by: Oka K, et al.
Published: (2018-12-01)

Inhaled budesonide for adults with mild-to-moderate asthma: a randomized placebo-controlled, double-blind clinical trial
by: Ana Luisa Godoy Fernandes, et al.
Published: (2001-09-01)

Characterization of glomerular extracellular matrix in IgA nephropathy by proteomic analysis of laser-captured microdissected glomeruli
by: Flavia Teodora Ioana Paunas, et al.
Published: (2019-11-01)

Management of IgA Nephropathy in Pediatric Patients
by: Sophie Schroda, et al.
Published: (2022-05-01)

Impact of gut microbiota in immunoglobulin A nephropathy; a letter to the editor to the recent findings
by: Mozhgan Kameli Khouzani, et al.
Published: (2024-01-01)

IgA nephropathy: a review of existing and emerging therapies
by: Sahibzadi Mahrukh Noor, et al.
Published: (2023-05-01)

Immunoglobulin A (IgA) Nephropathy in Protocol Graft Kidney Biopsy done at six months Post Transplantation in a Tertiary Care Center Hospital of Nepal
by: Midhan Shrestha, et al.
Published: (2017-08-01)

Correlation of pathologic findings of IgA nephropathy with clinical and laboratory data with regards to the Oxford-MEST-C classification
by: Mahoor Abedzadeh, et al.
Published: (2023-10-01)

The Effectiveness of Budesonide in the Treatment of Asthma Attacks in Children: A Systematic Review and Meta-Analysis
by: Akefeh Ahmadi Afshar, et al.
Published: (2023-06-01)

Efficacy and safety of immunosuppressive treatment in IgA nephropathy: a meta-analysis of randomized controlled trials
by: Zheng Zhang, et al.
Published: (2019-08-01)

Long-Term Outcomes of Kidney Transplant Recipients with Glomerulonephritides by Induction Type and Steroid Avoidance
by: Prasanth Ravipati, et al.
Published: (2022-02-01)

Chronic kidney disease: a review of proteomic and metabolomic approaches to membranous glomerulonephritis, focal segmental glomerulosclerosis, and IgA nephropathy biomarkers
by: Amir Taherkhani, et al.
Published: (2019-12-01)

Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study
by: Ya-zi Yang, et al.
Published: (2019-08-01)

The effectiveness and safety of corticosteroid therapy for IgA nephropathy with crescents: a prospective, randomized, controlled study
by: Mengjun Liang, et al.
Published: (2022-01-01)

Validation of the Oxford classification of IgA nephropathy for pediatric patients from China
by: Le Weibo, et al.
Published: (2012-11-01)

Co-existence of thin basement membrane nephropathy with other glomerular pathologies; a single center experience
by: Rizwan A. Qazi, et al.
Published: (2015-10-01)

Randomized Trial on the Effect of an Oral Spleen Tyrosine Kinase Inhibitor in the Treatment of IgA Nephropathy
by: Frederick W.K. Tam, et al.
Published: (2023-12-01)

IgA Nephropathy: Current Treatment and New Insights
by: Dimitra Petrou, et al.
Published: (2023-06-01)

Significance of immunohistochemical findings in Oxford classification of IgA nephropathy: The need for more validation studies
by: Muhammed Mubarak
Published: (2013-07-01)

The Association between Serum Hemoglobin and Renal Prognosis of IgA Nephropathy
by: Tae Ryom Oh, et al.
Published: (2021-01-01)

Life Expectancy for Patients From the Southeastern United States With IgA Nephropathy
by: M. Colleen Hastings, et al.
Published: (2018-01-01)